APNmAb005 vs VY7523
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline
APNmAb005
Developed by APRINOIA Therapeutics
NCT05344989 · Phase 1 · status unknown
This is a randomized, placebo-controlled study with full blinding of participants, care providers, and assessors, though it is an early, safety-focused, first-in-human study in healthy volunteers rather than a disease-population efficacy trial, with small dose-cohort sizes. Results have not yet been posted.
No aligned efficacy figure on record for this race.
VY7523
Developed by Voyager Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | APNmAb005 | VY7523 |
|---|---|---|
| CDR-SB, change | —Not reported | —Not reported |
| ADAS-Cog11, change | —Not reported | —Not reported |
| ADCS-ADL, change | —Not reported | —Not reported |
| MMSE, change | —Not reported | —Not reported |
| Amyloid PET, change (centiloids) | —Not reported | —Not reported |
CDR-SB, change
- APNmAb005
- —Not reported
- VY7523
- —Not reported
ADAS-Cog11, change
- APNmAb005
- —Not reported
- VY7523
- —Not reported
ADCS-ADL, change
- APNmAb005
- —Not reported
- VY7523
- —Not reported
MMSE, change
- APNmAb005
- —Not reported
- VY7523
- —Not reported
Amyloid PET, change (centiloids)
- APNmAb005
- —Not reported
- VY7523
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
APNmAb005: no structured comparison results are available for Alzheimer's Disease.
VY7523: no structured comparison results are available for Alzheimer's Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: APNmAb005's landscape · VY7523's landscape